Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
Search
New initiative elevates the importance of CKD testing
Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition’s unknown nature and the benefits of com
Jardiance® (empagliflozin) Tablets Studied in CKD | Boehringer Ingelheim US
BI & Eli Lilly & Co. announce plans for a new trial investigating JARDIANCE for the treatment of CKD. View ISI, PI and Med Guide.
Social Impact | COVID-19 | Boehringer Ingelheim US
Click to find out more on how Boehringer Ingelheim (BI) is standing together with our communities to support the fight against the COVID-19 pandemic.
KDIGO’s 2024 Updated Guidelines Re-Emphasize Commitment to Comprehensive Testing for CKD
Mohamed Eid shares his thoughts on the updated KDIGO clinical practice guidelines, published in 2024, and the need for guidelines-directed care for CKD.
Ensuring Global Access to Corona Care | Boehringer Ingelheim US
BI has signed a communiqué with the Bill & Melinda Gates Foundation and 15 other companies committing to provide access to COVID-19 related services.
What to Expect from Your Vaccine | Boehringer Ingelheim US
Read more on how horse owners are encouraged to schedule a wellness exam with their veterinarians, including annual equine vaccinations.
Top-line Phase II Data for treatment of MASH
Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).
Cardio-Renal-Metabolic diseases
Cardio-Renal-Metabolic diseases
Country Management Committee: A Message | Boehringer Ingelheim US
Click here to read a statement from Boehringer Ingelheim on the tragic events in Uvalde, TX and how BI Cares is supporting victims and families.
More Potential
More Potential
Sunshine Act Compliance
Sunshine Act Compliance
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Swine Vaccine Combo for Two Diseases | Boehringer Ingelheim US
Click here to read more on the launch of the Boehringer Ingelheim innovative vaccine combination, protecting US swine from two viruses in one shot.
Contact Us
Contact Us
Dan’s Unique Story
Each cancer journey is unique. In 2018 Dan was diagnosed with a rare form of sarcoma called dedifferentiated liposarcoma. Learn more about Dan’s unique approach to life with DDLPS.
Your Milestones Drive Ours
Learn more about the experiences of living with nonsmall cell lung cancer and cholangiocarcinoma as well as caring for a loved one during a cancer journey.
Facing Lung Cancer: Keith’s Story
Facing Lung Cancer: Keith’s Story
Boehringer included on LinkedIn’s “Top Companies 2024” list
Investing in our people is at the core of what we do
Moving to Germany
We started in Germany, but we have offices all over the world.
We’re looking for SAP developers to join our Global IT Department
Are you looking to take the next step in your career? Our global IT department has new SAP developer positions available!
Medicine & Regulatory Affairs
Medicine & Regulatory Affairs
R&D - Transforming tomorrow
Manami Tsutsumi, Senior Associate Director in Research & Development describes what it is like working on the cutting edge of pharmaceutical development.
Welcome to Innovation @ Boehringer Ingelheim
Welcome to Innovation @ Boehringer Ingelheim
Arising Vaccines to Help Zoo Elephants | Boehringer Ingelheim US
Find out how Boehringer Ingelheim is developing vaccines to help North African zoo elephants suffering from deadly infections and illness.